Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

Melbourne-based biotech VC Boson Ventures has raised $10 million of a target $30 million fund and is positioning itself as a ...

On July 25, Leads Biolabs made its official debut on the Hong Kong Stock Exchange. Its shares surged as much as 117% intraday ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...

MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0452 ET – Philips’s strong quarterly results and guidance raise ...

MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.

The nearly 40-year-old law that created the Vaccine Injury Compensation Program has received a lot of attention this month.